PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-6.73%
G&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
55.79%
Other expenses change of 55.79% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
-5.86%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-5.86%
Both companies reducing total costs. Martin Whitman would check industry trends.
-72.88%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
55.79%
D&A growth while TRAW reduces D&A. John Neff would investigate differences.
-143.43%
EBITDA decline while TRAW shows 27.25% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
5.86%
Operating income growth below 50% of TRAW's 27.47%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-101.24%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-142.73%
Pre-tax income decline while TRAW shows 27.43% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-72.88%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-142.73%
Net income decline while TRAW shows 27.45% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-120.58%
EPS decline while TRAW shows 27.47% growth. Joel Greenblatt would examine position.
-120.58%
Diluted EPS decline while TRAW shows 27.47% growth. Joel Greenblatt would examine position.
10.21%
Share count reduction below 50% of TRAW's 0.03%. Michael Burry would check for concerns.
10.21%
Diluted share reduction below 50% of TRAW's 0.03%. Michael Burry would check for concerns.